1. Home
  2. ECBK vs MGNX Comparison

ECBK vs MGNX Comparison

Compare ECBK & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECB Bancorp Inc.

ECBK

ECB Bancorp Inc.

N/A

Current Price

$16.90

Market Cap

144.3M

Sector

Finance

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$2.75

Market Cap

115.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ECBK
MGNX
Founded
1919
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
144.3M
115.8M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
ECBK
MGNX
Price
$16.90
$2.75
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.40
AVG Volume (30 Days)
7.2K
1.5M
Earning Date
04-23-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.62
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16.14
P/E Ratio
$25.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.55
$0.99
52 Week High
$20.05
$3.50

Technical Indicators

Market Signals
Indicator
ECBK
MGNX
Relative Strength Index (RSI) 39.88 56.94
Support Level $15.86 $1.46
Resistance Level $16.53 $3.50
Average True Range (ATR) 0.45 0.24
MACD -0.06 -0.02
Stochastic Oscillator 13.53 47.65

Price Performance

Historical Comparison
ECBK
MGNX

About ECBK ECB Bancorp Inc.

ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: